Abstract |
Despite its function as an inhibitor of urokinase and tissue-type plasminogen activator (PA), PA inhibitor-1 (PAI-1) has a paradoxical protumorigenic role in cancer, promoting angiogenesis and tumor cell survival. In this review, we summarize preclinical evidence in support of the protumorigenic function of PAI-1 that has led to the testing of small-molecule PAI-1 inhibitors, initially developed as antithrombotic agents, in animal models of cancer. The review discusses the challenges and the opportunities that lay ahead to the development of efficacious and nontoxic PAI-1 inhibitors as anticancer agents.
|
Authors | Veronica R Placencio, Yves A DeClerck |
Journal | Cancer research
(Cancer Res)
Vol. 75
Issue 15
Pg. 2969-74
(Aug 01 2015)
ISSN: 1538-7445 [Electronic] United States |
PMID | 26180080
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
|
Copyright | ©2015 American Association for Cancer Research. |
Chemical References |
- Antineoplastic Agents
- Plasminogen Activator Inhibitor 1
- SERPINE1 protein, human
|
Topics |
- Animals
- Antineoplastic Agents
(pharmacology)
- Apoptosis
(physiology)
- Disease Models, Animal
- Humans
- Mice
- Molecular Targeted Therapy
(methods)
- Neoplasms
(drug therapy, pathology)
- Neovascularization, Pathologic
(drug therapy)
- Plasminogen Activator Inhibitor 1
(metabolism, physiology)
|